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Abstract: Introduction: There is evidence that early intervention contributes to improving the
prognosis and course of first-episode psychosis (FEP). However, further randomised treatment
clinical trials are needed. Objectives: The aim of this study was to compare the efficacy of a combined
clinical treatment involving Cognitive Behavioural Therapy (CBT) as an adjunctive to treatment-as-
usual (TAU) (CBT+TAU) versus TAU alone for FEP. Patients and methods: In this multicentre, single-
blind, randomised controlled trial, 177 participants were randomly allocated to either CBT+TAU or
TAU. The primary outcome was post-treatment patient functioning. Results: The CBT+TAU group
showed a greater improvement in functioning, which was measured using the Global Assessment
Functioning (GAF) and Functioning Assessment Short Test (FAST), compared to the TAU group
post-treatment. The CBT+TAU participants exhibited a greater decline in depressive, negative, and
general psychotic symptoms; a better awareness of the disease and treatment adherence; and a
greater increase in brain-derived neurotrophic factor levels than TAU participants. Conclusions:
Early intervention based on a combined clinical treatment involving CBT as an adjunctive to standard
treatment may improve clinical and functional outcomes in FEP.
Keywords: first-episode psychosis; early intervention; treatment; outcome; randomised controlled trial
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1. Introduction
First-episode psychosis (FEP) is characterised by relapses, especially if not adequately
treated. This may have a negative impact on clinical and functional outcomes in the long
term [1]. Factors that have been associated with poorer outcomes include a poor premorbid
adjustment, comorbid substance use disorders, greater severity of negative symptoms,
history of suicide attempts and suicidal ideation, longer duration of untreated psychosis
(DUP), and lack of treatment adherence [2]. Brain-derived neurotrophic factor (BDNF) is a
neurotrophin that plays a critical role in neurodevelopment and brain plasticity, regulating
the function, survival, repair, and differentiation of neurons [3]. Moreover, BDNF has been
suggested to be a useful neurobiological biomarker of early-onset schizophrenia [4–10].
A systematic review and meta-analysis conducted by Sanada et al. [7] revealed that the
effect of psychological and non-pharmacological treatments on BDNF levels has been
scarcely studied; however, according to the existing literature, they could potentially have
an influence on this biological parameter.
The first five years after the onset of the illness, i.e., ‘the critical period’, might be
an indicator of long-term prognosis and is when FEP patients are more likely to relapse.
Patients in this period are also more responsive to treatment than in later stages of the
illness [11]. Early treatment of FEP during this period is crucial to prevent relapses and re-
duce disabilities caused by the disease. There is convincing evidence that early intervention
may contribute to improvement in the prognosis and course of FEP. Early intervention is
focused on increasing treatment adherence and disease awareness, improving symptomatic
and functional outcomes, and reducing relapses and hospitalisations [12]. Clinical practice
guidelines for the early treatment of psychosis recommend an integrated approach based
on evidence-based psychosocial treatments, such as cognitive behavioural therapy (CBT),
family therapy, and/or psychoeducation, as an adjunctive to pharmacological treatment
(13–19). These early intervention programmes for psychosis have demonstrated feasibility
and effectiveness in improving symptomatic and functional outcomes in FEP. Patients
treated during the earliest stages of psychosis experienced fewer symptoms, relapses, and
disability and showed a better functioning and quality of life, compared to patients who re-
ceived treatment-as-usual (TAU) [13–28]. While evidence of psychosocial interventions for
FEP has shown them to be effective in improving symptoms and functionality, additional
high-quality randomised clinical trials (RCTs) with representative samples of FEP patients
that allow for generalisation of the results are needed. A larger number of trials of a good
methodological quality are also required to determine the most effective psychological
treatments for FEP patients.
Accordingly, we conducted a RCT to compare the efficacy of a combined clinical
treatment for FEP involving a CBT adjunctive to TAU (CBT+TAU) versus TAU alone. The
data were compared at baseline and post-treatment. The primary objective of this study
was to assess the improvements in patient functioning. The secondary objectives were:
(1) to compare the efficacy of CBT+TAU versus TAU in improving psychotic and mood
(anxiety and depressive) symptoms; (2) to compare the treatment adherence and awareness
of disease in CBT+TAU vs. TAU; and (3) to compare the BDNF levels between the groups.
2. Materials and Methods
2.1. Participants
This was a multicentre, single-blind RCT registered in 2013 (NCT01783457). The study
protocol was described in a previous article by Barbeito et al. [29]. This RCT complied with
the CONSORT (CONsolidated Standards of Reporting Trials) guidelines, checklist, and
flow diagram (Figure 1).
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The recruitment of FEP patients was conducted between January 2011 and June 2015. 
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the Ene 2.0 software package. Based on similar previous studies [26,30], to achieve a 90% 
power to detect differences of 6 points or more between groups in the mean of the primary 
outcome (Global Assessment of Functioning, GAF) [31], and assuming an alpha risk of 
0.05, 130 patients were needed for each group. 
The patients needed to be between 18–45 years old and to have received a diagnosis 
of FEP, according to the 4th edition text-revised of the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-IV-TR) [32], within the previous five years, which could in-
clude either schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, 
delusional disorder, non-specified psychotic disorder, bipolar disorder with psychotic 
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power to detect differences of 6 points or more between groups in the mean of the primary
outco e (Global Assess ent of Functioning, GAF) [31], and assuming an alpha risk of
0.05, 130 patients were needed for each group.
The patients needed to be between 18–45 years old and to have received a diagnosis
of FEP, according to the 4th edition text-revised of the Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV-TR) [32], within the previous five years, which could in-
clude either schizophreniform disorder, schizoaffective disorder, brief psychotic disorder,
delusional disorder, non-specified psychotic disorder, bipolar disorder with psychotic
symptoms, or major depressive disorder with psychotic symptoms. The exclusion criteria
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were intellectual disability, organic brain disorders or the presence of comorbidities that
could hinder communication, and substance use disorder as the primary diagnosis.
2.2. Instruments
Sociodemographic (age, sex, level of education, and living and employment status)
and clinical (detailed below) data were collected using a clinical interview at baseline. The
clinical variables were also gathered during the post-treatment assessment.
2.2.1. Primary Outcome
The primary outcome was the level of post-treatment functioning, as measured by the
Global Assessment of Functioning (GAF) scale [31], which evaluates general activity and
functioning, and the Functioning Assessment Short Test (FAST) [33]. These were used to
assess six areas of functioning: autonomy, occupational functioning, cognitive functioning,
financial issues, interpersonal relationships, and leisure time. This scale has shown strong
psychometric properties in Spanish individuals with FEP [34].
2.2.2. Secondary Outcomes
Clinical variables, including clinical global impression, psychosis, anxiety and depres-
sive symptoms, treatment adherence, and awareness of disease assessed at baseline and at
post-treatment, were evaluated using an extensive battery of instruments.
The patients were diagnosed according to the DSM-IV-TR criteria using the Structured
Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Axis I
Disorders (SCID-I) [35].
The Clinical Global Impression Scale (CGI) [36] was used to measure the severity
and improvement in global symptoms. CGI has two components: CGI-Severity (CGI-S),
which rates illness severity, and CGI-Improvement (CGI-I), which rates changes from the
initiation of treatment.
Positive, negative, and general psychotic symptoms were assessed using the Positive
and Negative Syndrome Scale (PANSS) [37,38].
In order to measure the anxiety experienced by the subject in the previous week
(anxiety-state) and usual reactions to certain situations (anxiety-trait), the State-Trait Anxi-
ety Inventory (STAI) [39,40] was used.
Depressive symptomatology was assessed with the Hamilton Rating Scale for Depres-
sion (HRSD) [41,42].
Patient disease awareness was quantified using the Scale Unawareness of Mental Dis-
order (SUMD) [43,44], and the 4-item Morisky Medication Adherence Scale (MMAS) [45,46]
was used to explore the attitudes of patients towards their treatment, categorising patients
according to a good or bad adherence.
Plasma BDNF levels were analysed using a BDNF Sandwich enzyme-linked im-
munosorbent assay (ELISA) kit (CYT306; EMD Millipore Corporation, Billerica, MA, USA),
according to the manufacturer’s instructions. Blood cells were immediately separated
from plasma and processed. Standard curves were constructed using plasma duplicates.
The absorption at 450 nm was measured with a Synergy HT microplate reader (BioTek
Instruments, Winooski, VT, USA). The minimum detection limit was 7.8 pg/mL, and the
assay range was from 7.8 to 500 pg/mL. The intra- and inter-assay coefficients of variation
for the BDNF ELISA kits were +3.7% and +8.5%, respectively.
2.3. Procedure
The patients were recruited from different assistance levels of psychiatric care (includ-
ing the outpatient clinic, day hospital, and inpatient unit) of five centres associated with
the Center for Biomedical Research in the Mental Health Network (CIBERSAM): Araba
University Hospital, Hospital Clinic of Barcelona, Clinic University Hospital of Valencia,
University Hospital of Bellvitge, and University of Valencia. The patients needed to be
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psychopathologically stable prior to the start of the psychological intervention; therefore,
the treatment was administered after discharge.
After signing informed consent, the patients were randomised to one of the treatment
groups (TAU or combined clinical treatment) using random allocation software. The
allocation sequence was designed by an independent person not otherwise involved in
the trial.
The patients were evaluated at baseline and at post-treatment (which corresponds to
the end of the psychological treatment in the case of the intervention group). At these two
time points, plasma samples were collected to determine BDNF levels. The subjects of both
treatment groups were assessed by an evaluator who was not the therapist who developed
the intervention. The assessment was thus carried out by a researcher who was blind to
the patient allocation process. The evaluators of all the centres were trained to use scales
for inter-rater reliability by rating each of the scales with practical cases. For each scale, the
inter-rater reliability was higher than or close to 0.8, thus ensuring the inter-rate reliability
of patient assessments: (SCID-I (kappa = 0.88; CGI (kappa = 0.94), PANSS, kappa = 0.80;
STAI, kappa = 0.77; GAF, kappa = 0.95; HDRS, kappa = 0.79; and SUMD, kappa = 0.81;
MMAS, kappa = 0.94, FAST, kappa = 0.88). The therapists from all centres received an
8-h face-to-face training session and were provided with the same materials that would
later be offered to the patients in the intervention programme. To further enhance the
reliability, doubts that arose during the treatment administration were addressed by the
coordinating centre via video conferencing (Web Ex Training CENTER). TAU was provided
in all centres, according to the standard procedures of the Spanish National Health Service
for FEP patients. In the two treatment groups, medication was allowed to be adjusted when
necessary by the assigned psychiatrist in order to guarantee participant welfare, according
to ethical standards.
2.4. Intervention Programme
The patients were randomly assigned to one of the treatment groups (either TAU or
combined clinical treatment).
TAU refers to the standard treatment provided to FEP patients. This includes phar-
macological treatment and regular sessions with the assigned psychiatrist and a multi-
disciplinary team in each centre. TAU includes physical care, career counselling, and the
provision of unstructured information to families about disease symptoms, treatment,
and prognosis.
The combined clinical treatment involved TAU plus an adjuvant individual CBT
intervention. The intervention programme was implemented in all participating centres,
addressing the same content and following the same structure. It was composed of 14 one-
hour sessions fortnightly (±3 days) for a period of 6.5–7.5 months. The first part of the
program (sessions 1–9) was composed of psychoeducational sessions aimed at improving
patients’ insight into their illness, treatment adherence, prodromal identification, early
intervention to prevent relapses, and a healthy lifestyle. The second part of the intervention
(sessions 10–14) included cognitive behavioural techniques for symptom and thought
management (anxiety management techniques and social and problem-solving skills). The
patients were offered the possibility of using a telephone helpline between sessions if
they had any questions related to the content of the sessions or their status. The program
included the following sessions:
1. What is a first episode of psychosis?
2. Challenge and importance of insight into vulnerability.
3. Symptom recognition.
4. Prevention of relapses: protective and risk factors.
5. Detection of prodromes.
6. What can I do if I perceive that the symptoms are emerging again?
7. Treatment adherence.
8. Healthy lifestyles: sleep and sexuality.
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9. Healthy lifestyles: substance use.
10. Anxiety management techniques (I).
11. Anxiety management techniques (II).
12. Social skills: assertiveness techniques.
13. Problem-solving techniques.
14. Final doubts and farewell.
2.5. Statistical Analyses
All statistical analyses were performed using SPSS Statistics for Windows (Win-
dows v23.0), with the significance level set at p ≤ 0.05.
The baseline sociodemographic and clinical characteristics of the IT and the TAU
groups were compared using χ2-tests for categorical variables and Student’s t-test for
independent samples for quantitative variables.
Within-group changes (pre-post treatment) in symptomatology, functioning, and
BDNF levels were examined with Student’s t-test for paired samples. McNemar tests for
dichotomous variables were used to analyse changes in adherence.
An analysis of covariance (ANCOVA) was performed in order to determine differences
between groups in terms of clinical mean changes between the baseline and post-treatment.
The baseline values were used as covariates to eliminate the possible influence of initial
score variances on the outcomes. The partial eta squared (η2p) was also calculated to assess
the effect size. Since adherence was assessed using dichotomous scores, the differences
were evaluated using logistic regression models adjusted for baseline adherence.
Finally, we analysed the influence of clinical improvements in the functional out-
comes of each group. First, a simple linear regression was performed, using the GAF
post-treatment score as the dependent variable and post-treatment clinical variables as
independent variables. The variables found to be significant in the univariate regression
were entered into the final multivariate model.
3. Results
3.1. Sociodemographic and Clinical Baseline Characteristics of the Sample
The initial sample was composed of 184 FEP patients (92 for each intervention group).
Of these subjects, 7 (1 patient of the TAU group and 6 patients of the CBT+TAU group) were
excluded from the analysis for not having attended all intervention sessions or the post-
treatment assessment. As a result, the final sample consisted of 177 patients, of whom 91
(51.4%) were assigned to the TAU group and 86 (48.6%) to the CBT+TAU group (Figure 1).
A total of 105 (59.3%) subjects were male, and 72 (40.7%) were female. Additionally, 67.9%
(39.2% and 28.7%, respectively) were employed and/or students. Most of the patients (141)
(82.5%) were single, and 106 (72.1%) had completed secondary education. The diagnoses
were similarly distributed in both groups, with the most frequent diagnosis being non-
specified psychotic disorder (χ2 = 2.500; p = 0.776). The majority of patients were treated
with second-generation antipsychotics (97.2%), polytherapy (79.8%), and monotherapy
(20.2%). There were no clinical or functional differences at baseline between the CBT+TAU
and the TAU groups. There were also no differences between the groups regarding BDNF
levels (t = −0.839; p = 0.404).
The baseline sociodemographic and clinical characteristics of each group are repre-
sented in Table 1.
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Table 1. Baseline sociodemographic and clinical characteristics of the sample.
Variable Total (n = 177) CBT + TAU TAU t/χ2 p
Sex Women 72 (40.7%) 39 (45.3%) 33 (36.3%) χ2 = 1.512 0.219
Age 28.53 ± 8.97 27.74 ± 7.66 29.27 ± 10.03 t = −1.136 0.258
Occupation
Employed 69 (39.2%) 31 (35.7%) 39 (42.5%)
χ2 = 0.863Unemployed 57 (32.2%) 30 (34.5%) 27 (29.9%) 0.650
Student 51 (28.7%) 26 (29.8%) 25 (27.6%)
Education level
Primary school 6 (3.4%) 1 (1.4%) 5 (5.3%)
χ2 = 2.784 0.249Secondary school 128 (72.1%) 67 (77.5%) 61 (67.1%)
College 43 (24.5%) 18 (21.1%) 25 (27.6%)
Civil status
Single 146 (82.5%) 72 (83.3%) 74 (81.6%)
χ2 = 0.136Married 23 (12.9%) 10 (11.9%) 13 (13.8%) 0.934
Divorced 8 (4.7%) 4 (4.8%) 4 (4.6%)
Diagnosis Non-specified psychotic disorder 118 (66.7%) 58 (67.4%) 60 (65.9%)
χ2 = 2.500 0.776
Bipolar disorder with
psychotic symptoms 23 (13%) 13 (15.1%) 10 (11%)
Schizophreniform disorder 17 (9.6%) 6 (7%) 11 (12.1%)
Brief psychotic disorder 13 (7.3%) 6 (7%) 7 (7.7%)
Major depressive disorder with
psychotic symptoms 3 (1.7%) 1 (1.2%) 2 (2.2%)
Delusional disorder 3 (1.7%) 2 (2.3%) 1 (1.1%)
Treatment Antipsychotics 171 (97.2% 85 (98.8%) 86 (95.6%) χ2 = 1.716 0.190
Benzodiazepines 77 (43.8%9 35 (40.7%) 42 (46.7%) χ2 = 0.637 0.425
Mood stabilisers 24 (13.6%) 12 (14%) 12 (13.3%) χ2 = 0.014 0.905
Antidepressants 20 (11.4%) 11 (12.8%) 9 (10%) χ2 = 0.340 0.560
FAST 31.61 ± 15.81 33,09 ± 15,519 30,16 ± 16,053 t = −1.218 0.225
GAF 58.54 ± 11.0 59.63 ± 9.99 56.78 ± 11.82 t = 1.133 0.259
CGI-S 7.64 ± 5.75 7.74 ± 5.94 7.55 ± 5.60 t = 0.224 0.823
CGI-I 8.65 ± 7.77 9.06 ± 8.10 8.26 ± 7.46 t = 0.677 0.499
PANSS P 14.16 ± 6.95 13.40 ± 6.46 15.36 ± 7.71 t = −1.960 0.052
PANSS N 13.69 ± 6.27 14.48 ± 6.96 13.19 ± 5.83 t = 1.635 0.104
PANSS PG 29.19 ± 7.98 29.64 ± 8.68 28.77 ± 7.2 t = 0.886 0.377
HDRS 11.75 ± 7.40 12.46 ± 8.22 11.07 ± 6.51 t = 1.241 0.219
STAI-State 24.82 ± 10.90 23.87 ± 10.96 26.14 ± 10.59 t = −0.892 0.374
SUMD 4.94 ± 3.18 5.50 ± 3.05 5.47 ± 3.95 t = −0.054 0.957
MMAS 97 (54.8%) 52 (60.0%) 45 (49.4%) χ2 = 1.940 0.164
BDNF (pg/Ml) 6.95 ± 5.77 7.66 ± 6.79 6.49 ± 5.05 t = −0.839 0.404
3.2. Clinical and Functional Outcomes of FEP Patients
Regarding the within-group mean changes, there was a significant improvement
between the baseline and post-treatment, except for CGI-S, both in the CBT+TAU (t = 1.519;
p = 0.133) and the TAU groups (t = 0.380; p = 0.705). There were no changes in BDNF levels
between the baseline and post-treatment in any of the groups (Table 2).
Table 2. Within-group changes (pre/post-treatment).
Group CBT + TAU TAU
Variable Pre Post t (p) Pre Post t (p)
FAST 33.43 ± 15.531 15.15 ± 16.425 7.638 (≤0.001) 30.96 ± 20.05 20.05 ± 15.221 6.109 (≤0.001)
GAF 61.24 ± 10.62 76.03 ± 13.60 −7.669 (≤0.001) 56.92 ± 12.03 69.58 ± 13.91 −7.310 (0.001)
CGI-S 6.74 ± 5.43 6.09 ± 6.61 1.519 (0.133) 7.16 ± 5.41 6.99 ± 6.68 0.380 (0.705)
CGI-I 8.08 ± 7.81 7.07 ± 7.57 2.131 (0.037) 7.48 ± 7.03 6.25 ± 6.09 3.033 (0.003)
Panns P 13.34 ± 6.44 8.47 ± 3.22 6.365 (≤0.001) 15.39 ± 7.66 10.39 ± 4.90 5.705 (≤0.01)
Panns N 14.78 ± 7.49 10.55 ± 5.71 5.394 (≤0.001) 13.41 ± 6.29 11.39 ± 5.43 3.787 (≤0.001)
Panns G 30.17 ± 10.33 21.35 ± 7.60 6.738 (≤0.001) 28.81 ± 7.29 23.33 ± 6.67 6.861 (≤0.001)
HDRS 12.31 ± 8.31 5.24 ± 5.58 6.434 (≤0.001) 11.30 ± 6.28 6.65 ± 4.96 8.066 (≤0.001)
STAI-State 24.11 ± 10.91 19.05 ± 9.18 3.192 (0.002) 25.97 ± 11.30 21.28 ± 7.93 3.309 (0.002)
SUMD 4.67 ± 3.05 3.07 ± 2.88 6.067 (≤0.001) 4.64 ± 2.97 3.93 ± 3.03 2.697 (0.008)
MMAS (good) 1 51 (60.0%) 55 (72.4%) p = 0.052 1 38 (43.7%) 36 (45.6%) p = 0.690 1
BDNF (pg/Ml) 7.66 ± 6.79 9.76 ± 6.78 −1.760; (0.090) 6.49 ± 5005 6.95 ± 4.39 −0.675 (0.503)
1 p value obtained with the Mcnemar test for dichotomous variables.
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In relation to the progression (baseline/post-treatment) of the CBT+TAU and TAU,
significant differences were found in clinical outcomes (Table 3). For the primary outcome,
the CBT+TAU group showed a greater improvement in functioning, as assessed by GAF
(F = 6.269; p = 0.013, η2p = 0.04) and FAST (F = 5.468; p = 0.021, η2p = 0.04). Regarding
secondary outcomes, the CBT+TAU T showed a greater decline in positive (PANSS P)
(F = 6.214; p = 0.014, η2p = 0.04), negative (PANSS N) (F = 4.008; p = 0.047, η2p = 0.03), and
general (PANSS G) (F = 4.626; p = 0.033, η2p = 0.03) psychotic symptoms, compared to the
TAU group. The CBT+TAU group also had a greater reduction in depressive symptoms
(HDRS) (F = 4.078; p = 0.045, η2p = 0.03) and better disease awareness (SUMD) (F = 6.564;
p = 0.011, η2p = 0.04), compared to the TAU group. In addition, the percentage of patients
with a good adherence increased significantly in the CBT+TAU group (12.4% vs. 1.9%;
B = 1.002, p = 0.007, OR = 2.723). There was also an increase in BDNF levels in the CBT+TAU
group, compared to the TAU group (F = 3.923; p = 0.050, η2p = 0.05). The effect sizes for all
these clinical outcome differences were medium and high in terms of adherence outcomes,
with an OR = 2.723.
Table 3. A comparison of the course of the disease, adjusting for pre-treatment scores (ANCOVA).
Variable CBT + TAU ∆ TAU ∆ F p η2p
FAST −18.28 ± 20.73 −10.91 ± 15.88 5.468 0.021 0.04
GAF 14.79 ± 16.70 12.66 ± 15.78 6.269 0.013 0.04
CGI-S −0.65 ± 3.66 −0.17 ± 3.98 0.605 0.438 0.00
CGI-I −1.01 ± 3.98 −1.24 ± 3.62 0.379 0.539 0.00
Panns P −4.87 ± 6.67 −5.00 ± 7.94 6.214 0.014 0.04
Panns N −4.22 ± 6.83 −2.02 ± 4.84 4.008 0.047 0.03
Panns G −8.83 ± 11.34 −5.48 ± 7.19 4.626 0.033 0.03
HDRS −7.07 ± 9.51 −4.65 ± 5.16 4.078 0.045 0.03
STAI State −5.05 ± 11.95 −4.69 ± 11.69 1.494 0.224 0.01
SUMD −1.60 ± 2.28 −0.71 ± 2.43 6.564 0.011 0.04
MMAS (good) 1 12.4% 1.9% 1.002 0.007 2.723
BDNF (pg/Ml) 2.10 ± 6.30 0.46 ± 4.55 3.923 0.050 0.05
1 Variable analysed by logistic regression, adjusted for pre-treatment adherence. The data are represented as the B coefficient, p-value, and
odds ratio.
3.3. Influence of Clinical Improvements on Functional Outcomes
In the CBT+TAU group, all the post-treatment clinical variables had an impact on the
functional outcomes, whereas in the TAU group, the HDRS (B = −0.859; 95% CI: −1.216
to −0.503; p ≤ 0.001) and STAI-S (B = −0.563; 95% CI: 72.742 to 90.601; p = 0.006) scores
were associated with a poorer functioning. When significant variables in the simple linear
regression were included in the multivariate model, the results indicated that improvements
in the CGI-I (B = −0.693; 95% CI: −0.966 to −0.420; p ≤ 0.001), PANNS-N (B = −0.647;
95% CI: −0.985 to −0.309; p ≤ 0.001), and STAI-S (B = −0.232; 95% CI: −0.455 to −0.010)
post-treatment scores were associated with a better functioning in the CBT+TAU group,
whereas in the TAU group, only the HDRS (B = −2.091; 95% CI: −2.635 to −1.548; p = 0.000)
was associated with functioning.
4. Discussion
This randomised controlled trial aimed to compare the efficacy of a CBT+TAU treat-
ment of FEP versus TAU alone, comparing the results at baseline with post-treatment
outcomes. The patients in the intervention group exhibited a more pronounced improve-
ment in functioning, treatment adherence, and awareness of their disease, as well as a
greater reduction in depressive, negative, and general psychotic symptoms post-treatment,
as compared to TAU. Additionally, the BDNF levels were higher in the intervention group
than in the TAU group. Our findings support the importance of early psychological
intervention, as an adjunctive to pharmacological treatment, for clinical and functional
improvements in FEP. In a recent systematic review, meta-analysis, and meta-regression,
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Correll et al. [21] analysed 10 RCTs and concluded that early intervention programmes
were associated with better clinical and functional outcomes than TAU at post-treatment,
including hospitalisation risk, bed days, the severity of symptoms, and global functioning.
The primary outcome of the study is that patients who received CBT+TAU, in con-
sonance with other studies [20–28], had better functional outcomes than those who only
received TAU. Notably, improvements in clinical symptomatology had an influence on
functional outcomes. Specifically, improvements in the severity of symptoms and anxious
and negative psychotic symptoms were associated with better functioning in the interven-
tion group, whereas in the TAU group, only depressive symptoms were associated with
poor functioning. A functional impairment is present in early psychosis and, although the
symptoms of FEP generally improve in the short term, patients often develop poor func-
tionality during post-treatment follow-up and even 12 months after early intervention [47].
Therefore, interventions targeting functional recovery in FEP are necessary, and our results
show that psychoeducational intervention could be useful in improving clinical symptoms,
which influences functional outcomes in these patients.
One of the main findings of our study is that the BDNF levels were improved in the
CBT+TAU group, compared to TAU at post-treatment. This suggests that BDNF levels
are reduced at the onset of psychosis and that a psychological intervention could restore
the plasma concentrations of this neurotrophic factor. These results are consistent with
several clinical studies reporting reduced BDNF levels in FEP, which might be a marker of
early-onset schizophrenia. Inflammatory processes, neurotrophin levels, and functional
status seem to be related to disease onset [4–10]. Specifically, BDNF receptor expression is
associated with the treatment response and overall functioning at disease onset and after
one-year follow-up [6].
The second main finding of the study is that, in agreement with other studies [23,25],
the intervention was effective in reducing psychotic symptoms. The psychological treat-
ment had a remarkable impact on negative symptoms, which are usually associated with
a worse response to pharmacological treatment in FEP [48,49]. Moreover, the persistence
of negative symptoms at follow-up leads to a worse functioning in patients [50], which
highlights the significant role of negative symptoms in early interventions. Other studies
also concluded that specific psychological interventions are useful in ameliorating negative
symptoms in early psychosis [25,51].
Our psychological intervention also proved, as in other studies [17], to be effective
in improving depressive symptoms. Depressive symptoms are common in FEP and often
persist over the course of the disease. In a recent systematic review and meta-analysis
conducted by McGinty and Upthegrove [52], depressive symptoms in FEP were associ-
ated with a poorer long-term functioning and a reduced chance of achieving functional
remission. In a previous study, we reported that subclinical depressive symptoms were
also associated with cannabis abuse, which could be a predictor of negative outcomes in
FEP [53]. Hence, depressive symptoms should be a therapeutic target in FEP patients to
prevent the development of an unfavourable clinical and functional disease course.
The third finding of the study is that psychoeducational intervention was effective
in improving adherence and disease awareness in FEP. A lack of treatment adherence
is associated with poor clinical and functional outcomes. Moreover, a high number of
FEP patients are non-adherent to treatment at 12-month follow-up, which increases the
risk of relapse and rehospitalisations [2,11,54,55]. Our results, according to other studies,
revealed that psychoeducational intervention could be crucial for improving adherence
to medication and illness course, and that clinical outcomes of patients not only depend
on initial treatment but also on continued adherence to treatment. The study conducted
by Randall et al. [56] found that the Early Psychosis Prevention and Intervention Service
programme was associated with an increased adherence to antipsychotic medication use
during and after the program, thus improving patient conditions. Early intervention in FEP
must include psychosocial interventions focused on increasing adherence and improving
therapeutic alliance. A lack of insight, negative attitudes toward medication, and a bad
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therapeutic alliance are factors associated with non-adherence [57] and which could be
targeted by such interventions to achieve better outcomes in patients with FEP.
In conclusion, the results of this study suggest that early interventions in FEP based
on a combined clinical treatment involving a CBT adjunctive to TAU may help improve
clinical and functional outcomes, in addition to restoring the BDNF levels of FEP patients.
Hence, treating FEP with a standard treatment alone may not be effective enough for the
majority of patients, and an integrative approach is necessary to optimise the functional
outcomes [58].
This study has some limitations. First, long-term follow-up should be considered in
future research to determine long-term benefits and assess other aspects, such as relapses
or rehospitalisations. Secondly, it should be considered that the components and number
of sessions of different psychological intervention programmes may vary between studies.
Third, our psychological treatment programme has an individual format, while others
employ a group approach. Moreover, in our study, although all the centres included are
public and belong to the Spanish National Health Service, with a set time of 30 min for each
visit, there are some slight differences between the centres. Additionally, the differences
in the time and attention devoted to each treatment arm should be taken into account in
the interpretation of the results. A little more time was spent with patients in the enriched
treatment group than with the control group. According to ethical requirements, the TAU
group received the psychological intervention after the completion of the study. Another
limitation is that, although minimal medication dose adjustments were allowed during
the trial, this variable might have an influence on the study outcomes. Finally, because the
pre-calculated size was not reached, the final size of the groups was reduced. As this could
affect the pre-calculated power of the study, we corrected the statistical calculation, and the
final power of the study was set to 80%.
The study also has important strengths, which give our findings relevant implications
for clinical practice. CBT+TAU has proven to be a useful therapeutic approach to treat and
achieve recovery in early psychosis. Moreover, the results are generalisable, because they
were obtained in a multicentre study that included a large sample of patients recruited in
different Spanish psychiatric admission centres for acute psychosis.
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